Endothelial L-Selectin Ligands in Sinus Mucosa during Chronic Maxillary Rhinosinusitis

Toppila‐Salmi, Sanna; Myller, Jyri; Torkkeli, T; Muhonen, Jarkko; Renkonen, Jutta; Rautiainen, Markus; Renkonen, Risto

doi:10.1164/rccm.200406-775oc

Cited by 12 publications

(20 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with the literature on L-selectin ligand expression in chronic inflammatory diseases, the overall expression of MECA-79 in inferior turbinate specimens of our allergic subjects appeared to be higher compared with what was previously found on inferior turbinate specimens of healthy controls [27]. The L-selectin ligand expression in the allergic turbinates is also higher than the expression that was previously found in maxillary sinus mucosa of chronic rhinosinusitis patients [26]. The nasal mucosa of house dust mite allergic rhinitis patients must be chronically inflamed.…”

Section: Discussionsupporting

confidence: 90%

“…Normally, the expression of L-selectin ligands is restricted to high endothelial venules (HEVs) in lymphoid tissues. However, in diseases characterized by chronic inflammation such as asthma, Crohn’s disease and rheumatoid arthritis induction of L-selectin ligands is seen in postcapillary endothelial cells in tissues other than lymphatic tissue [25,26]. It appears that the expression level of L-selectin ligands (as identified with MECA-79 expression) correlates with the extent of tissue eosinophilia and severity of inflammation in patients with chronic rhinosinusitis [26,27].…”

Section: Discussionmentioning

confidence: 99%

“…However, in diseases characterized by chronic inflammation such as asthma, Crohn’s disease and rheumatoid arthritis induction of L-selectin ligands is seen in postcapillary endothelial cells in tissues other than lymphatic tissue [25,26]. It appears that the expression level of L-selectin ligands (as identified with MECA-79 expression) correlates with the extent of tissue eosinophilia and severity of inflammation in patients with chronic rhinosinusitis [26,27]. In accordance with the literature on L-selectin ligand expression in chronic inflammatory diseases, the overall expression of MECA-79 in inferior turbinate specimens of our allergic subjects appeared to be higher compared with what was previously found on inferior turbinate specimens of healthy controls [27].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Characterisation of interleukin‐10 expression on different vascular structures in allergic nasal mucosa

Muller¹,

Egmond²,

Groot³

et al. 2014

Clinical & Translational All

View full text Add to dashboard Cite

BackgroundInterleukin-10 (IL-10) is a negative regulator of immune responses and was previously shown to be expressed by human nasal endothelial cells, while the adhesion molecule MECA-79 plays a role in trans-endothelial migration of immune competent cells. In this study we investigate the relationship between endothelial IL-10 and MECA-79 expression to address the question whether immune competent cells could be affected at the mucosal entry site.MethodsNasal turbinate biopsies were taken from house dust mite allergic patients, before and after nasal allergen provocation. Subsequent slides of biopsies were stained for IL10, MECA-79, CD34, and IL10-Receptor. Capillaries, arteries/veins, and sinusoids were evaluated separately.Results90% of sinusoids are IL-10 positive and all sinusoids are negative for MECA-79, while 4.8% of capillaries are positive for IL-10, and 2.2% are positive for MECA-79. Although about 47% of arteries/veins are positive for IL-10 and 57.1% are positive for MECA-79, only about 20% are positive for both markers. Furthermore, we showed that the myo-fibroblasts surrounding all sinusoids stain positive for IL10R.ConclusionsIL10 expression on vascular structures is not related to MECA expression for sinusoids and capillaries and only partly related on arteries/veins, however sinusoidal endothelial IL10 expression is always seen in combination with IL-10R expression of sinusoidal myo-fibroblasts.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterisation of interleukin‐10 expression on different vascular structures in allergic nasal mucosa

Muller¹,

Egmond²,

Groot³

et al. 2014

Clinical & Translational All

View full text Add to dashboard Cite

show abstract

“…The follow‐up data was available from the hospital's patient records or questionnaires from a total of 178 (87%) CRS patients. The CRS patients were from three preexisting studies . The first study data was collected from an initial study, which was a prospective follow‐up study that included two sets of patients who underwent maxillary sinus surgery between 2001 to 2002.…”

Section: Methodsmentioning

confidence: 99%

Factors affecting revision rate of chronic rhinosinusitis

Koskinen

Salo

Huhtala³

et al. 2016

Laryngoscope Investig Oto

View full text Add to dashboard Cite

ObjectiveChronic rhinosinusitis (CRS) is a variable multifactorial disease. It can be divided into forms with nasal polyps (CRSwNP) and without (CRSsNP). Sinus and/or nasal polypectomy surgery are considered if maximal conservative treatment is insufficient. The predictive factors of the need of revision surgery comprise mostly the CRSwNP phenotype and are not fully understood.Study DesignThe aim of this follow‐up study was to evaluate the factors associated with the revision surgery rate in CRS patients with variable extent of disease.MethodsData of CRS patients (N = 178) undergoing sinus surgery and/or nasal polypectomy in 2001 to 2010 were used. Patient characteristics and follow‐up data were collected from patient records and questionnaires. Associations were analyzed by Fisher's exact, Mann Whitney U, and the Kaplan‐Meier method with log‐rank test. Unadjusted Cox's proportional hazard models were used for 12 variables and were fitted for the need for revision sinus surgery and/or nasal polypectomy during follow‐up of in average 9 years.ResultsThe proportion of CRS patients who had undergone revision in 5 years was 9.6%. After adjustment, the following factors associated significantly with the need for recurrent CRS surgery: allergic rhinitis, corticosteroid treatment, previous surgery of CRS, and recurrent NP.ConclusionIncreased risk of progressive CRS phenotypes with the need for revision surgery would putatively be recognized by relatively simple clinical questions. Further studies with increased sample size are needed to evaluate whether these predictive factors would be relevant for developing better detection and management of progressive CRS.Level of Evidence2b.

show abstract

“…The up-regulation in HS-292 cells appears to occur through activation of the epidermal growth factor receptor and involves activation by proteases such as ADAM17 and/or MMP-9 (74). Studies in sinus (as opposed to bronchial) tissues from patients undergoing sinus surgery suggest that L-selectins may play a role in the migration of inflammatory cells into the tissue, which then activates mucus production through mechanisms as outlined above (75).…”

Section: Remodeling In Asthmamentioning

confidence: 99%

Update in Asthma 2005

Wenzel

Covar²

2006

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Endothelial L-Selectin Ligands in Sinus Mucosa during Chronic Maxillary Rhinosinusitis

Abstract: Our results suggest that functionally active L-selectin ligands might guide leukocyte traffic into maxillary sinus mucosa preferentially in patients with severe findings of chronic maxillary rhinosinusitis, thus leading to aggravation of the inflammation.

Cited by 12 publications

References 55 publications

Characterisation of interleukin‐10 expression on different vascular structures in allergic nasal mucosa

Characterisation of interleukin‐10 expression on different vascular structures in allergic nasal mucosa

Factors affecting revision rate of chronic rhinosinusitis

Update in Asthma 2005

Contact Info

Product

Resources

About